"Revenue for the second quarter of 2026 was $27.2 million" and "Overall... a net loss of $13.5 million" (CFO Grasman) contrasted with Q1’s "Revenue for the first quarter was $39.2 million" and "a net ...

Vaxart (VXRT) is scheduled to announce Q2 earnings results on Thursday, August 6th, after market close. The consensus EPS Estimate is -$0.21 and the consensus Revenue Estimate is $26.21M (-34.0% Y/Y).

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

As of August 6, 2024, the average one-year price target for Vaxart is $5.36/share. The forecasts range from a low of $2.52 to a high of $8.40. The average price target represents an increase of 805.33 ...

Vaxart Inc (VXRT) announced a significant partnership with Dynavax, potentially worth up to $700 million, which validates the potential of their oral COVID-19 vaccine platform. The partnership with ...

The FDA allowed Vaxart's clinical trial for its oral vaccine candidate The shares of Vaxart Inc (NASDAQ:VXRT) are up 7.2% at $7.71 this morning, following news that the U.S. Food and Drug ...

Vaxart Inc. Annual stock financials by MarketWatch. View the latest VXRT financial statements, income statements and financial ratios.